CSL Behring GmbH
EURO PLAZA 5i, Wagenseilgasse 3, 1120 Vienna
Focused on serving patients’ needs by using the latest technologies, CSL Behring develops and delivers a broad range of recombinant and plasma-based therapies that are used to treat coagulation disorders, primary immune deficiencies, and inflammatory neurological disorders as well as therapies that are used to treat hereditary angioedema and alpha-1 antitrypsin deficiency.
more than 20,000 worldwide
CSL Behring is a global biotherapeutics leader driven by our promise to save lives and improve the quality of live. Our mission is to discover, develop and launch innovative therapies that improve the quality of patients' lives.